Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria :~* The participant and/or participant's parent(s)/legal guardian(s) must provide written informed assent/consent prior to any protocol-related procedures being performed.~* The participant was \<18 years of age on the date of informed assent/consent.~* The participant had documented deficiency of acid sphingomyelinase as measured in peripheral leukocytes, cultured fibroblasts, or lymphocytes.~* The participant had a spleen volume greater than or equal to (\>=) 5 multiples of normal (MN) measured by magnetic resonance imaging (MRI); participants who had partial splenectomy were allowed if the procedure was performed \>=1 year before screening and the residual spleen volume was \>=5 MN.~* The participant's height was -1 Z-score or lower.~* A negative serum pregnancy test in female participants of childbearing potential.~* Female participants of childbearing potential and male participants must be willing to practice true abstinence in line with their preferred and usual lifestyle or use 2 acceptable effective methods of contraception.~Exclusion criteria:~* The participant had received an investigational drug within 30 days before study enrollment.~* The participant had any of the following medical conditions:~* An active, serious, intercurrent illness.~* Active hepatitis B or hepatitis C infection.~* Infection with human immunodeficiency virus (HIV).~* Cirrhosis (determined by clinical evaluation).~* Significant cardiac disease (eg, clinically significant arrhythmia, moderate or severe pulmonary hypertension or valvular dysfunction, or \<40 percent (%) left ventricular ejection fraction by echocardiogram).~* Malignancy diagnosed within the previous 5 years (except basal cell carcinoma).~* Any other extenuating circumstance that can significantly interfere with study compliance, including all prescribed evaluations and follow-up activities.~* The participant had acute or rapidly progressive neurological abnormalities.~* The participant was homozygous for SMPD1 gene mutations R496L, L302P, and fs330 or any combination of these 3 mutations.~* The participant had a delay of gross motor skills.~* The participant had a major organ transplant (eg, bone marrow, liver).~* The participant required use of invasive ventilatory support.~* The participant required use of noninvasive ventilatory support while awake and for greater than (\>)12 hours a day.~* The participant in the investigator's opinion, was unable to adhere to the requirements of the study.~* The participant had a platelet count \<60 × 10\^3/µL (based on the average of 2 screening samples obtained up to 24 hours apart).~* The participant had alanine aminotransferase or aspartate aminotransferase \>250 IU/L or total bilirubin \>1.5 mg/dL.~* The participant had an international normalized ratio (INR) \>1.5.~* The participant was unwilling or unable to abstain from ingesting alcohol the day before through 3 days after each infusion of olipudase alfa during the treatment period. Measuring alcohol concentration in blood was not required.~* The participant was scheduled during the study for in-patient hospitalization including elective surgery.~* The participant required medication(s) that may can decrease olipudase alfa activity (eg, fluoxetine, chlorpromazine; tricyclic antidepressants \[eg, imipramine, or desipramine\]).~* The participant was breast-feeding.~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Olipudase alfa (Type: EXPERIMENTAL): Participants received intravenous (IV) infusion of olipudase alfa once every 2 weeks (Q2W) for 64 weeks. Each participant underwent a dose escalation according to the following paradigm: 0.03, 0.1, 0.3, 0.3, 0.6, 0.6, 1.0, 2.0, 3.0 milligram per kilogram (mg/kg). Three (3) mg/kg was the target maintenance dose, which was maintained for the remaining duration of 64 treatment weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete